Skip to Content

'
Jan A. Burger, M.D., Ph.D

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

"Privatdozent" (lecturer) in Internal Medicine, Albert-Ludwigs University, School of Medicine, Freiburg, Germany
Faculty, Graduate School of Biomedical Sciences, University of Texas-Houston Health Science Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 428
Houston, TX 77030-4009
Room Number: Department of Leukemia, FC4.3032
Phone: 713-563-1487
Email: jaburger@mdanderson.org

Education & Training

Degree-Granting Education

1994 Albert Ludwigs University, School of Medicine, Freiburg, Germany, M.D., Ph.D., Magna cum laude, Medicine

Postgraduate Training

11/1999-9/2005 Fellowship, Instructor, Hematology/Oncology, Freiburg University Hospital, Freiburg, Germany, Professor Roland Mertelsmann
11/1996-10/1999 Postdoctoral Fellow, Hematology/Oncology, University of California, San Diego, San Diego, CA, Dr. Thomas J. Kipps
1/1995-10/1996 Residency, Internal Medicine, Freiburg University Hospital, Freiburg, Germany, Professor Roland Mertelsmann

Board Certifications

9/2005 Hematology/Oncology ("Schwerpunkt Hamatologie und Internistische Onkologie"). Landesaertztekammer Baden-Wurttemberg, Germany
5/2005 Internal Medicine ("Facharzt fur Innere Medizin"), Landesaerztekammer Baden-Wurttemberg, Germany
7/1996 Medical Board Licensing Certificate ("Approbation als Arzt")

Experience/Service

Academic Appointments

Assistant Professor, tenure track, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2005-8/2011
Director, Diagnostic Flow Cytometry Laboratory, Hematology/Oncology, Freiburg University, Freiburg, Germany, 2002-2005
Instructor and Fellow in Internal Medicine and Hematology/Oncology, Department of Internal Medicine, Freiburg University, Freiburg, Germany, 11/1999-9/2005
Postdoctoral Fellowship, Hematology/Oncology, University of California, San Diego (PI: Thomas J. Kipps, MD, PhD), San Diego, CA, 11/1996-10/1999
Medical Residency, Department of Internal Medicine, Division of Internal Medicine, Freiburg University Hospital, Professor Roland Mertelsmann, Freiburg, Germany, 1/1995-10/1996

Institutional Committee Activities

Study Section, Study Section Review Committee for Basic Research Projects under the Institutional Research Grants Program, 9/2011-present
Reviewer and Member; "Excellent Protocol Reviewer" in 2006, CRC, 2006-2011

Honors and Awards

2013-2018 Scholar in Clinical Research Award, Leukemia & Lymphoma Society
2013-2016 Faculty Scholar Award, University of Texas MD Anderson Cancer Center
2007 ASCO Career Development Award (CDA), ASCO
2006 ASCO Young Investigators Award (YIA), ASCO
2006 Kimmel Scholar Award, Sidney Kimmel Foundation for Cancer Research
2006 New Investigator Award, Leukemia Research Foundation
2006 Venia Legendi in Internal Medicine ("Privatdozent"), Albert-Ludwigs-University Freiburg, Freiburg, Germany
2001 Arthur Pappenheim Award, German Hematology Society (DGHO) for research in the field of hematology/CLL
1996-1998 Research Fellowship: Postdoctoral fellowship, The University of California, San Diego by the Deutsch Krebshilfe, Bonn, Germany
1994 Doctoral thesis: "The effects of peritonitis exudates on the chemotaxis of human neutrophils", degree "magna cum laude", Department of Surgery, 12/1994, Albert Ludwigs University of Medicine, Freiburg, Germany

Professional Memberships

American Association for Cancer Research (AARC)
Member, 2007-present
American Society of Clinical Oncology (ASCO)
Member, 2005-present
American Society of Hematology (ASH)
Member, 1997-present
European Hematology Association (EHA)
Member, 2008-present
German Society of Hematology/Oncology (Deutsche Gesellschaft fur Hamatologie und Onkologie/DGHO)
Member, 2000-present
SWOG (Southwest Oncology Group), Portland, OR
Member, 2013-present
The International Cancer Microenvironment Society
Group Member, 10/2013-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 8/2014. e-Pub 5/2014. PMID: 24859876.
2. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. e-Pub 8/2014. PMID: 25150798.
3. Ten Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. e-Pub 7/2014. PMID: 25050922.
4. Sivina M, Kreitman RJ, Arons E, Ravandi F, Burger JA. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol 166(2):177-88, 7/2014. e-Pub 4/2014. PMCID: PMC4104473.
5. Ponader S, Burger JA. Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. J Clin Oncol 32(17):1830-9, 6/2014. e-Pub 4/2014. PMID: 24778403.
6. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic leukemia. Blood 123(24):3727-32, 6/2014. e-Pub 4/2014. PMCID: PMC4067501.
7. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of chronic lymphocytic leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132-5, 6/2014. e-Pub 5/2014. PMID: 24829205.
8. Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14(3):231-8, 6/2014. e-Pub 12/2013. PMID: 24440659.
9. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 6/2014. e-Pub 4/2014. PMCID: PMC4055926.
10. Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. Nat Rev Clin Oncol 11(4):184-6, 4/2014. e-Pub 3/2014. PMID: 24642682.
11. Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, Lu H, Debose L, Burger JA, Andreeff M, Liu W, Baggerly KA, Kornblau SM, Doyle LA, Estey EH, Kantarjian HM. Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia. Clin Cancer Res 20(8):2226-35, 4/2014. e-Pub 2/2014. PMCID: PMC3989412.
12. Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28(4):973-5, 4/2014. e-Pub 10/2013. PMID: 24157581.
13. Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep 9(1):44-9, 3/2014. PMID: 24357428.
14. Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 32(9):897-904, 3/2014. e-Pub 2/2014. PMID: 24516016.
15. Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 3/2014. PMID: 24779033.
16. ten Hacken E, Burger JA. Molecular Pathways: Targeting the microenvironment in chronic lymphocytic leukemia- focus on the B cell receptor. Clin Cancer Res 20(3):548-56, 2/2014. e-Pub 12/2013. PMID: 24323900.
17. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15(1):48-58, 1/2014. e-Pub 12/2013. PMCID: PMC4134524.
18. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34(12):592-601, 12/2013. e-Pub 8/2013. PMCID: PMC3898793.
19. Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88(12):1024-9, 12/2013. e-Pub 9/2013. PMCID: PMC3849405.
20. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 12/2013. e-Pub 9/2013. PMCID: PMC3835390.
21. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 54(11):2385-2391, 11/2013. e-Pub 8/2013. PMID: 23425038.
22. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 11/2013. e-Pub 8/2013. PMID: 23943357.
23. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA. The Spiegelmer(R) NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemo-sensitization. Blood. e-Pub 11/2013. PMID: 24277076.
24. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Semin Cancer Biol. e-Pub 9/2013. PMID: 24018164.
25. Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger J, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 8/2013. e-Pub 7/2013. PMID: 23836561.
26. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32-42, 7/2013. e-Pub 6/2013. PMCID: PMC3772525.
27. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, Pierce S, Daver N, Garcia-Manero G, Faderl S, Nazha A, Konopleva M, Borthakur G, Burger J, Kadia T, Dellasala S, Andreeff M, Cortes J, Kantarjian H, Levis M. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 121(23):4655-62, 6/2013. e-Pub 4/2013. PMCID: PMC3674666.
28. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121(9):1501-9, 2/2013. e-Pub 12/2012. PMID: 23264597.
29. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 31(5):584-91, 2/2013. e-Pub 12/2012. PMID: 23270003.
30. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger J, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 12:50, 2013. e-Pub 6/2013. PMCID: PMC3671957.
31. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 8(12):e83830, 2013. e-Pub 12/2013. PMCID: PMC3871531.
32. Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24(6):643-9, 11/2012. e-Pub 9/2012. PMID: 22960555.
33. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger JA, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 118(18):4471-7, 9/2012. e-Pub 1/2012. PMID: 22282348.
34. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 26(8):1812-20, 8/2012. e-Pub 3/2012. PMID: 22460735.
35. Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 12(4):244-51, 8/2012. e-Pub 4/2012. PMID: 22534616.
36. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-83, 7/2012. e-Pub 2/2012. PMID: 22362000.
37. Eghtedar A, Verstovsek S, Estrov Z, Burger JA, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML). Blood 119(20):4614-8, 5/2012. e-Pub 3/2012. PMID: 22422826.
38. Saintigny P, Burger JA. Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13(71):287-97, 4/2012. PMID: 22541616.
39. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B. Th17 and non-Th17 IL-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97(4):599-607, 4/2012. e-Pub 11/2011. PMCID: PMC3347674.
40. Peled A, Wald O, Burger JA. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 21(3):341-53, 3/2012. e-Pub 1/2012. PMID: 22283809.
41. Burger JA. Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 7(1):26-33, 3/2012. e-Pub 11/2011. PMID: 22105489.
42. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 14(3):276-86, 3/2012. e-Pub 2/2012. PMCID: PMC3290742.
43. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-9, 2/2012. e-Pub 12/2011. PMID: 22180443.
44. Burger JA. The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. Expert Opin Med Diagn 6(1):49-57, 1/2012. e-Pub 11/2011. PMID: 23480620.
45. Davids MS, Burger JA. Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol 3(S1), 2012. e-Pub 2/2012. PMCID: PMC3404599.
46. Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger JA, O'Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 42(12):1989-2000, 12/2011. e-Pub 7/2011. PMID: 21733558.
47. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 29(31):4088-95, 11/2011. e-Pub 10/2011. PMID: 21969505.
48. Burger JA, Ford RJ. The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and, emerging targeted therapies. Semin Cancer Biol 21(5):308-12, 11/2011. e-Pub 9/2011. PMID: 21945516.
49. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger JA, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 118(14):3818-23, 10/2011. e-Pub 8/2011. PMID: 21821712.
50. Burger JA, Hoellenriegel J. Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia. Oncotarget 2(10):737-8, 10/2011. e-Pub 10/2011. PMCID: PMC3248155.
51. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger JA, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 117(20):4689-95, 10/2011. e-Pub 3/2011. PMID: 21456010.
52. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-98, 9/2011. e-Pub 7/2011. PMID: 21725050.
53. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-12, 9/2011. e-Pub 7/2011. PMID: 21803855.
54. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 8/2011. e-Pub 6/2011. PMID: 21670470.
55. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger JA, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 8/2011. e-Pub 7/2011. PMID: 21750315.
56. Manshouri T, Estrov Z, Quintás-Cardama A, Burger JA, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 71(11):3831-40, 6/2011. e-Pub 4/2011. PMID: 21512135.
57. Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma 52 Suppl 2:94-8, 6/2011. e-Pub 3/2011. PMID: 21438839.
58. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 11(4):621-30, 4/2011. PMID: 21504328.
59. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 3/2011. e-Pub 1/2011. PMID: 21245487.
60. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 117(5):1662-9, 2/2011. e-Pub 11/2010. PMID: 21115978.
61. Burger JA. Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia. Hematology Am Soc Hematol Educ Program 2011:96-103, 2011. PMID: 22160019.
62. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Semin Cancer Biol 20(6):424-30, 12/2010. e-Pub 9/2010. PMID: 20883788.
63. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 28(35):e732-4, 12/2010. e-Pub 9/2010. PMID: 20823404.
64. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger JA, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-2077, 9/2010. e-Pub 5/2010. PMID: 20466853.
65. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced response in CLL primary cells. Blood 116(7):1083-91, 8/2010. e-Pub 5/2010. PMCID: PMC2938131.
66. Quiroga MP, Burger JA. BCR-Mediated Decrease of CXCR4 and CD62L in CLL - Letter. Cancer Res 70(12):5194; author reply 5195, 6/2010. e-Pub 5/2010. PMID: 20501831.
67. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 3/2010. e-Pub 1/2010. PMID: 20054352.
68. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger JA, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2/2010. e-Pub 11/2009. PMID: 19895616.
69. Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res 15(24). e-Pub 12/2009. PMCID: PMC2795094.
70. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis. Blood 114(20):4441-50, 11/2009. e-Pub 9/2009. PMID: 19762485.
71. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 114(16):3367-75, 10/2009. e-Pub 7/2009. PMID: 19636060.
72. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 9/2009. e-Pub 6/2009. PMID: 19567878.
73. Burger JA, Gandhi V. The lymphatic tissue microenvironments in Chronic Lymphocytic Leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood 114(12):2560-1, 9/2009. PMID: 19762501.
74. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 8/2009. e-Pub 6/2009. PMID: 19517462.
75. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 114(5):1029-37, 7/2009. e-Pub 6/2009. PMID: 19491390.
76. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549-57, 5/2009. e-Pub 3/2009. PMID: 19318683.
77. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113(19):4604-13, 5/2009. e-Pub 2/2009. PMID: 19228923.
78. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger JA, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients with Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 4/2009. e-Pub 2/2009. PMID: 19224852.
79. Burger JA, Stewart DJ. CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opin Investig Drugs 18(4):481-90, 4/2009. PMID: 19335276.
80. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-Level Expression of the T Cell Chemokines CCl3 and CCL4 by Chronic Lymphocytic Leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood 113(13):3050-8, 3/26/2009. e-Pub 12/12/2008. PMID: 19074730.
81. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B-cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113(1):149-53, 1/2009. e-Pub 10/2008. PMCID: PMC2614629.
82. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23(1):43-52, 1/2009. e-Pub 11/2008. PMID: 18987663.
83. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G, Burger JA, Cortes J. Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112(13):4839-42, December 15, 2008, 12/2008. PMID: 18818391.
84. Berg T, Fliegauf M, Burger JA, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 93(11):1728-33, 11/2008. PMID: 18790797.
85. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia. Blood 110(9):3316-3325, 11/2007. e-Pub 7/2007. PMID: 17652619.
86. Burger JA, Bürkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137(4):288-96, 5/2007. PMID: 17456052.
87. Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in Acute Myelogenous Leukemia. Blood 109(2):786-791, 1/2007. e-Pub 8/2006. PMID: 16888090.
88. Burger JA, Schmitt-Gräff A, Bürkle A, Seiler L, Finke J. Imatinib Mesylate-induced long-term Remission in Extramedullary T Cell Lymphoid Blastic Phase of Chronic Myelogenous Leukemia. Leuk Lymphoma 47(11):2427-30, 11/2006. PMID: 17107924.
89. Bossaller L,Burger JA, Draeger R, Grimbacher B, Knoth R, Plebani A, Durandy A, Baumann U, Schlesier M, Welcher AA, Peter HH, Warnatz K. ICOS deficiency is associated with a severe reduction of CCR5+ germinal center helper T cells. J Immunol 177:4927-32, 10/2006.
90. Burger JA, Kipps TJ. CXCR4, a key receptor in the cross-talk between tumor cells and their microenvironment. Blood 107(5):1761-7, 3/2006. e-Pub 11/2005. PMID: 16269611.
91. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA. Small Peptide Inhibitors of the CXCR4 Chemokine Receptor (CD184) Antagonize the Activation, Migration and Antiapoptotic Responses of CXCL12 in CHronic Lymphocytic Leukemia B Cells. Blood 106(5):1824-30, 9/2005. e-Pub 5/2005. PMID: 15905192.
92. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24(27):4462-71, 6/2005. PMID: 15806155.
93. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3 dependent pathway. Oncogene 24(12):2067-2075, 3/2005. PMID: 15688008.
94. Zeiser R, Mikesch K, Fisch P, Schaefer HE, Burger JA. Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. Br J Haematol 125(6):679, 6/2004. PMID: 15180856.
95. Hartmann TN, Burger M, Burger JA. The role of adhesion molecules and chemokine receptor CXCR4 (CD184) in small cell lung cancer. J Biol Regul Homeost Agents 18(2):126-130, Apr-Jun, 4/2004. PMID: 15471215.
96. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Mönting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis - a single centre experience. Br J Haematol 124(6):762-8, 3/2004. PMID: 15009064.
97. Burger M, Glodek A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fujii N, Kipps TJ, Burger JA. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22(50):8093-8101, 11/2003. PMID: 14603250.
98. Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta 1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudomperipolesis). Br J Haematol 122(4):579-589, 8/2003. PMID: 12899713.
99. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstädt H. Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 168(12):6244-6252, 6/2002. PMID: 12055238.
100. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 43(3):461-466, 3/2002. PMID: 12002747.
101. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 99(3):1030-1037, 2/2002. PMID: 11807009.
102. Aivado M, Schulte K, Henze L, Burger JA, Finke J, Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 29(4 Suppl 13):19-22, 2002.
103. Horner AA, Widhopf GF, Burger JA, Takabayashi K, Cinman N, Ronaghy A, Spiegelberg HL, Raz E. Immunostimulatory DNA inhibits IL-4 dependent lgE synthesis by human B cells. J Allergy Clin Immunol 108(3):417-423, 9/2001. PMID: 11544462.
104. Burger JA, Zvaifler NJ, Tsukada N, Firestein GS, Kipps TJ. Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. J Clin Invest 107(3):305-15, 2/2001. PMCID: PMC199194.
105. Burger JA, Mendoza RB, Kipps TJ. Plasmids encoding granulocytemacrophage colony-stimulating factor and CD 154 enhance the immune response to genetic vaccines. Vaccine 19(15-16):2181-2189, 2/2001. PMID: 11228391.
106. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood (Cover Illustration) 96(8):2655-63, 10/2000. PMID: 11023495.
107. Burger JA, Baird SM, Powell HC, Sharma S, Eling DJ, Kipps TJ. Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice. Br J Haematol 108(3):641-652, 3/2000. PMID: 10759724.
108. Zvaifler NJ, Marinova-Mutafchieva L, Adams G, Edwards CJ, Moss J, Burger JA, Maini RN. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res 2(6):477-488, 2000. e-Pub 8/2000. PMCID: PMC17820.
109. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94(11):3658-3667, 12/1999. PMID: 10572077.
110. Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. J Immunol 163(4):2017-2022, 8/1999. PMID: 10438939.
111. Sach M, Burger JA, Engelhardt A, Ketelsen UP, Schollmeyer P. [Temporary hemiparesis and Raynaud symptoms in eosinophilic fasciitis]. Internist (Berl) 38(7):688-91, 7/1997. PMID: 9333603.
112. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 11(2):281-3, 2/1997. PMID: 9009093.
113. Sach M, Bauermeister K, Burger JA, Loetscher P, Elsner J, Schollmeyer P, Dobos GJ. Inverse MCP-1/L-8 ratio in effluents of CAPD patients with peritonitis and in isolated cultured human peritoneal macrophages. Nephrol Dial Transplant 12(2):315-320, 2/1997. PMID: 9132652.
114. Burger JA, Ochs A, Wirth K, Berger DP, Mertelsmann R, Engelhardt R, Roessle M, Haag K. The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol 8(2):200-202, 2/1997. PMID: 9093733.
115. Burger JA, Schöffel U, Sach M, Jacobs E, Kownatzki E, von Specht BU, Farthmann EH. Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Eur J Surg 161(9):647-53, 9/1995. PMID: 8541423.
116. Sach M, Loetscher P, Burger JA, Knopf HP, Schollmeyer P, Dobos GJ. MCP-1 levels are elevated in peritonitis fluid from CAPD patients due to secretion by peritoneal macrophages. Adv Perit Dial 11:19-23, 1995. PMID: 8534702.

Editorials

1. Burger JA. Osteopontin: an unhealthy sleep remedy for ALL. Blood 121(24):4814-5, 6/2013. PMID: 23766457.
2. Burger JA. BRAF mutation: supporting diversity in HCL. Blood 119(14):3193-4, 4/2012. PMID: 22493212.
3. Burger JA. Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leuk Lymphoma 53(1):3-4, 1/2012. e-Pub 9/2011. PMID: 21830996.
4. Burger, JA . Angiopoietin-2 in CLL. Blood 116(4):508-09, 7/2010.
5. Burger JA. CXCR4 in acute myelogenous leukemia (AML): When too much attraction is bad for you. Leuk Res 18(4):747-48, 6/2009. e-Pub 12/2008. PMID: 19091405.
6. Burger JA and Gandhi V. Tissue microenvironments and drug resistance in Chronic Lymphocytic Leukemia: ABT-737 must overcome the same hurdles as our older drugs. Faculty 1000 Medicine, 6/2009.
7. Burger, JA . Fledgling prognostic markers in CLL. Blood 110(12):3820-21, 12/2007.
8. Burger JA. No cell is an island unto itself: The stromal microenvironment in chronic lymphocytic leukemia. Leuk Res 31(7):887-8, 7/2007. e-Pub 1/2007. PMID: 17234265.

Abstracts

1. Randhawa S, Ghosh D, Peled A, Davis RE, Burger J. Targeting the CXCR4 Chemokine Receptor Thwarts Stromal Cell Mediated Drug Resistance in B-Cell Acute Lymphoblastic Leukemia (B-ALL). AACR 2014 Annual Meeting, 4/2014.
2. Kim E, Koehrer S, Rosin N, Wang Z, Thomas D, Ravandi R, Kornblau S, Kantarjian H, O'Brien S, Estrov Z, Buggy J, Muschen M, Davis R, Burger J. Bruton′s Tyrosine Kinase Inhibitor Ibrutinib Interferes With Constitutive and Induced Pre-B Cell Receptor Signaling In B-Cell Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts), 12/2013.
3. Burger J. Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. Blood (ASH Annual Meeting Abstracts) (#866), 12/2013.
4. Rosin N, Kim E, Koehrer S, Wang Z, O’Brien S, Wierda W, Thomas D, Estrov Z, Kantarjian H, Lannutti B, Quéva C, DavisR, Burger J. Gene Expression Profiling and Western Blot Analyses Demonstrated Down Regulation of Pre-B Cell Receptor Signaling after GS-1101 Treatment in Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts), 12/2013.
5. ten Hacken E, Scielzo C, Wierda W, Keating M, O’Brien S, Ghia P, Caligaris-Cappio F, Burger J. Ibrutinib differentially interferes with surface IgM and IgD BCR signaling kinetics in Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), 12/2013.
6. Hoellenriegel J, Hartmann E, Rosenwald A, O’Brien S, Keating M, Wierda W, Buggy J, Burger J. Longitudinal Gene Expression Profiling Reveals Down-regulation of BCR Signaling-related Genes in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib plus Rituximab. Blood (ASH Annual Meeting Abstracts), 12/2013.
7. Köhrer S, Davis R, Coffey G, Kim E, Rosin N, ten Hacken E, O’BrienS, Wierda W, Estrov Z, Thomas D, Kantarjian H, Wang Z, Jumaa H, Burger J. Pre-BCR Signaling Activity Predicts Sensitivity to Syk Kinase Inhibition In B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood (ASH Annual Meeting Abstracts), 12/2013.
8. Kim E, Koehrer S, Rosin NY, Thomas DA, Ravandi F, Kornblau SM, Kantarjian HM, O'Brien S, Estrov Z, Buggy JJ, Burger JA. Activity of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) in B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood (ASH Annual Meeting Abstracts) (#2569), 12/2012.
9. Sivina M, Kreitman RJ, Arons E, Buggy JJ, Ravandi F, Burger JA. Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Blocks Hairy Cell Leukemia (HCL) Survival, Proliferation, and BCR Signaling: A New Therapeutic Approach for HCL. Blood (ASH Annual Meeting Abstracts) (#1802), 12/2012.
10. Falchi L, Kantarjian HM, Quintas-Cardama A, O'Brien S, Jabbour EJ, Ravandi F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE. Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) (#164), 12/2012.
11. Ravandi F, Alattar ML, Levis MJ, Garcia-Manero G, Richie MA, Daver NG, Faderl S, Andreeff M, Borthakur G, Burger JA, Kadia TM, Grunwald MR, Dellasala SE, Cortes JE, Kantarjian HM. Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood (ASH Annual Meeting Abstracts) (#1519), 12/2012.
12. Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien SM, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts) (#3619), 12/2012.
13. Jain P, Trinh LX, Benjamini O, Lerner S, Wang X, Ferrajoli A, Burger JA, Estrov Z, Wierda WG, Kantarjian HM, O'Brien S, Abruzzo LV, Keating MJ. Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality. Blood (ASH Annual Meeting Abstracts) (#2890), 12/2012.
14. Köhrer S, Coffey G, Kim E, Rosin NY, Sinha U, Pandey A, Shehata M, Ulrich Jäger M, O'Brien SM, Wierda WG, Estrov Z, Thomas D, Kantarjian HM, Burger JA. Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) (#3532), 12/2012.
15. Boumber Y, Thomas DA, Ravandi F, Rytting ME, Love MR, Lu H, Garris R, Cortes JE, O'Brien S, Burger JA, Kantarjian HM, Konopleva M. Final Report of a Phase I/II Study of Hyper-CVAD Plus RAD001 (Everolimus) in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia. Blood (ASH Annual Meeting Abstracts) (#3567), 12/2012.
16. Wierda WG, Balakrishnan K, Ferrajoli A, O'Brien S, Burger JA, Kadia TM, Cortes JE, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi VV. Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy. Blood (ASH Annual Meeting Abstracts) (#437), 12/2012.
17. Rosin NY, Köehrer S, Kim E, O'Brien SM, Wierda WG, Thomas DA, Estrov Z, Kantarjian HM, Lannutti BJ, Burger JA. In Vitro Effects of PI3Kδ Inhibitor GS-1101 (Cal-101) in Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) (#3534), 12/2012.
18. Hoellenriegel J, O'Brien S, Keating MJ, Wierda WG, Buggy JJ, Burger JA. In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton’s Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial. Blood (ASH Annual Meeting Abstracts) (#186), 12/2012.
19. Andreeff M, Zeng Z, Kelly MA, Wang R, McQueen T, Duvvuri S, Nowshad G, Borthakur G, Burger JA, Kadia TM, Jabbour E, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and Elimination of FLT3-ITD+ Acute Myelogenous Leukemia (AML) Stem/Progenitor Cells by Plerixafor/G-CSF/Sorafenib : Results From a Phase I Trial in Relapsed/Refractory AML Patients. Blood (ASH Annual Meeting Abstracts) (#142), 12/2012.
20. Zboralski D, Hoellenriegel J, Maasch C, Kruschinski A, Burger JA. Mode of Action of the SDF-1/CXCL12 Inhibiting Spiegelmer® Nox-A12 and Its Impact On Chronic Lymphocytic Leukemia (CLL) Cell Motility and Chemosensitization. Blood (ASH Annual Meeting Abstracts) (#318), 12/2012.
21. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Kornblau SM, Andreeff M, Garris R, Wang SA, Estrov Z, Cortes JE, O'Brien S. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood (ASH Annual Meeting Abstracts) (#3572), 12/2012.
22. Jain P, Kantarjian HM, Thomas DA, Ravandi F, Kadia TM, Burger JA, Borthakur G, Cortes JE, Daver N, Jabbour EJ, Koller CA, Konopleva M, Pemmaraju N, Kelly MA, Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) (#1501), 12/2012.
23. Bulian P, Shanafelt TD, Peppe C, Fegan C, Del Poeta G, Gaidano G, Rossi D, Baldini L, Cro L, Nuckel H, Burger JA, Gattei V. Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients. Blood (ASH Annual Meeting Abstracts) (#3871), 12/2012.
24. Takahashi K, Sivina M, Oki Y, Fayad LE, Neelapu SS, Kwak LW, Xiao L, Huang X, Fu K, Chan WC, Vose JM, Kantarjian HM, Keating M, Burger JA. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) (#2709), 12/2012.
25. Rozovski U, Calin G, Tetsirp S, D'Abundo L, Harris D, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien SM, Wierda WG, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) (#2886), 12/2012.
26. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman JP, Grant B, Jones JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A, Clow F, Kunkel L, James DF, O'Brien S. The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood (ASH Annual Meeting Abstracts) (#189), 12/2012.
27. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, Lerner S, Zacharian G, Huang X, James DF, Buggy JJ, Kantarjian HM, O'Brien SM. The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. Blood (ASH Annual Meeting Abstracts) (#187), 12/2012.
28. Yilmaz M, Kantarjian HM, Jabbour EJ, O'Brien SM, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger JA, Pierce SA, Quintás-Cardama A, Cortes JE. The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. Blood (ASH Annual Meeting Abstracts) (#1693), 12/2012.
29. Wierda WG, Balakrishnan K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi V. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients with CLL. Blood (ASH Annual Meeting Abstracts) 118 (#3901), 11/2011.
30. Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D. A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 118 (#2858), 11/2011.
31. Ponader S, Balasubramanian S, Pham LV, Jun C, Archito TT, Wang M, O'Brien S, Wierda WG, Keating MJ, Ford RJ, Burger JA. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target,. Blood (ASH Annual Meeting Abstracts) 118 (#3688), 11/2011.
32. Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC). Blood (ASH Annual Meeting Abstracts) 118 (#981), 11/2011.
33. Sivina M, Kreitman RJ, Peled A, Ravandi F, Burger JA. Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. Blood (ASH Annual Meeting Abstracts) 118 (#1760), 11/2011.
34. Chen SS, Buggy JJ, Chang BY, Burger JA, Chiorazzi N. Btk Inhibitor, PCI-32765, Delays CLL Progression in a TCL1 Adoptive Transfer Model by Impairing Migration and Cell Proliferation. ASH Annual Meeting Abstracts 118 (#982), 11/2011.
35. Evans E, Tester R, Aslanian S, Chaturvedi P, Mazdiyasni H, Ponader S, Tesar B, Sheets M, Nacht M, Stiede K, Witowski S, Lounsbury H, Petter R, Brown JR, Burger JA, Singh J, Westlin WF. Clinical Development of AVL-292; A Potent, Selective Covalent Btk Inhibitor for the Treatment of B Cell Malignancies. Blood (ASH Annual Meeting Abstracts) 118 (#3485), 11/2011.
36. Alattar ML, Kantarjian HM, Jabbour E, Quintas-Cardama A, Burton EM, Borthakur G, Verstovsek S, Wierda WG, Konopleva M, Burger JA, O'Brien S, Cortes JE. Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP. Blood (ASH Annual Meeting Abstracts) (#745), 11/2011.
37. Liu-Dumlao T, Kantarjian HM, Quintas-Cardama A, Jabbour E, Burger JA, Alvarado Y, Burton EM, Trinh LX, Ravandi F, Ferrajoli A, O'Brien S, Cortes JE. Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML). Blood (ASH Annual Meeting Abstracts) 118 (#2761), 11/2011.
38. Ravandi F, Thomas DA, O'Brien S, Garris R, Faderl S, Shan J, Borthakur G, Burger JA, Ferrajoli A, Kebriaei P, Champlin R, Estrov Z, Wang SA, Jorgensen JL, Luthra R, Cortes JE, Kantarjian HM. Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy 118 (#1453), 11/2011.
39. Thomas DA, Kantarjian HM, Faderl S, Wierda W, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad L, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood (ASH Annual Meeting Abstracts) 118 (#2698), 11/2011.
40. Pozadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang SA, Lerner S, Ferrajoli A. Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy. Blood (ASH Annual Meeting Abstracts) 118 (#3907), 11/2011.
41. Lee HJ, Kantarjian HM, Thomas DA, Faderl S, Koller C, Ferrajoli A, Jabbour E, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda WG, Burger JA, Cortes JE, O'Brien S, Ravandi F. Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 118 (#1512), 11/2011.
42. Lee HJ, O'Brien S, Kantarjian HM, Ravandi F, Faderl S, Koller C, Konopleva M, Verstovsek S, T Kadia, Garcia-Manero G, Borthakur G, William G. Wierda, WG, Burger JA, Thomas DA, Cortes JE. Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. Blood (ASH Annual Meeting Abstracts) 118 (#1518), 11/2011.
43. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood (ASH Annual Meeting Abstracts) 118 (#1524), 11/2011.
44. Wierda WG, O'Brien S, Ferrajoli A, Koller CA, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Lerner S, Keating MJ. Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclophosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL. Blood (ASH Annual Meeting Abstracts) 118 (#3902), 11/2011.
45. Li P, Zhiming L, Harris D, Ferrajoli A, Wang Y, Hazan-Halevy I, Grgurevic S, Wierda G, Burger JA, O'Brien S, Faderl S, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3 Induces Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Receptor-α Expression in Chronic Lymphocytic Leukemia (CLL) Cells. Blood (ASH Annual Meeting Abstracts) 118 (#3879), 11/2011.
46. O'Brien S, Burger JA, Blum KA, Furman RR. The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. Blood (ASH Annual Meeting Abstracts) 118 (#983), 11/2011.
47. Fiorcari S, Brown WS, McIntyre BW, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Marasca R, Lannutti BJ, Estrov Z, Burger JA. The PI3 Kinase Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures. Blood (ASH Annual Meeting Abstracts) 118 (#1769), 11/2011.
48. Hoellenriegel J, Zboralski D, Estrov Z, Wierda WG, Keating M, Kruschinski A, Burger JA. The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration. Blood (ASH Annual Meeting Abstracts) 118 (#3878), 11/2011.
49. Daver N, Kantarjian HM, Garcia-Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, Jabbour E. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts) 118 (#3629), 11/2011.
50. H Ghanem, H Kantarjian, G Garcia-Manero, F Ravandi, Faderl S, Cortes JE, Reyes A, O'Brien SM, G Borthakur, Kadia TM, Burger JA, Konopleva M, E Jabbour. A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Journal of Clinical Oncology, 2011 ASCO Annual Meeting 29(15):6568, 6/2011.
51. Byrd C, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, O'Brien SM. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. Journal of Clinical Oncology, 2011 ASCO Annual Meeting 29(15 (Suppl)):6508 (#6508), 5/2011.
52. Jabbour E, Garcia-Manero G, Ghanem HA, Ravandi F, Faderl S, Cortes JE, Reyes AS, O'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Kantarjian HM. A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS. Blood (ASH Annual Meeting Abstracts) 116 (#2188), 11/2010.
53. Ponader S, Buggy J, O'Brien S, Wierda WG, Keating M, Burger JA. Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo. Blood (ASH Annual Meeting Abstracts) 116 (#45), 11/2010.
54. Jabbour E, Kantarjian H, Cornelison AM, Kadia T, Welch MA, Abruzzo LV, Burger JA, Ferrajoli A, Garcia-Manero G, Cortes JE. Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML). Blood (ASH Annual Meeting Abstracts) 116 (#1232), 11/2010.
55. Thomas DA, O'Brien S, Cortes JE, Faderl S, Wierda WG, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Burger JA, Garris R, Romaguera J, Hagemeister F, Kantarjian H. Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. Blood (ASH Annual Meeting Abstracts) 116 (#1781), 11/2010.
56. Frenzel LP, Schulz A, Pallasch CP, Claus R, Ponader S, Burger JA, Hallek M, Plass C, Wendtner CM. Microenvironment Influences Expression of TOSO – a Novel NF-Kappa B Target Gene In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#695), 11/2010.
57. Ravandi F, Jorgensen J, O'Brien S, Thomas DA, Faderl S, York S, Burger JA, Ferrajoli A, Pierce S, Keating M, Kantarjian H. Phase II Study of Sequential Therapy with Cladribine Followed by an Extended Course Rituximab in Patients with Hairy Cell Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#2458), 11/2010.
58. Eghtedar A, Verstovsek S, Cortes JE, Estrov Z, Burger JA, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Newton R, Kantarjian H, Ravandi F. Phase II Study of the JAK2 Inhibitor, INCB018424, In Patients with Refractory Leukemias Including Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML). Blood (ASH Annual Meeting Abstracts) 116 (#509), 11/2010.
59. Hoellenriegel J, Meadows SA, Wierda WG, Keating MJ, Lannutti B, Burger JA. Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurselike Cells (NLC), In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#116), 11/2010.
60. Andritsos L, Byrd JC, Jones JA, Hewes B, Kipps TJ, Hsu FJ, Burger JA. Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#2450), 11/2010.
61. Badoux X, Al-Ameri AM, O'Brien S, Wierda WG, Burger JA, Faderl S, Estrov Z, Lerner S, Keating M, Ferrajoli A. Retrospective Analysis of the Experience with Rituximab and Methylprednisone In Elderly Patients with CLL. Blood (ASH Annual Meeting Abstracts) 116 (#4638), 11/2010.
62. Hoellenriegel J, Coffey G, Sinha U, Pandey A, Wierda WG, Keating MJ, Burger JA. Spleen Tyrosine Kinase (Syk) Inhibitors Block B Cell Receptor Signaling and Survival In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 116 (#3604), 11/2010.
63. Sivina M, Hartmann E, Boucas J, Keating MJ, Wierda WG, Herling M, Rosenwald A, Burger JA. Stroma-Induced TCL1 Expression In Chronic Lymphocytic Leukemia Cells Is Associated with Down Regulation of TCL1A-Targeting miRNAs. Blood (ASH Annual Meeting Abstracts) 116 (#52), 11/2010.
64. Burger JA, O'Brien S, Fowler N, Advani R, Sharman JP, Furman RR, Izumi R, Buggy J, Loury D, Hamdy A, Byrd JC, Blum CA. The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. Blood (ASH Annual Meeting Abstracts) 116 (#57), 11/2010.
65. Parikh SA, Wierda WG, Badoux X, O'Brien SM, Ferrajoli A, Faderl S, Burger JA, Lerner S, Kantarjian H, Keating MJ. Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL). J Clin Oncol (2010 ASCO Annual Meeting) 28(7) (#6519), 6/2010.
66. Vigil CE, Kantarjian H, Thomas DA, O'Brien SM, Ravandi Kashani F, Koller, CA, Burger JA, Garris RS, Baccus MD, Faderl S. Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL). J Clin Oncol (2010 ASCO Annual Meeting) 28((15)) (#6524), 6/2010.
67. Sivina M, Hartmann E, Krupnik D, LaPushin R, Keating M, Kipps T, Rosenwald A, Wierda W, Burger JA. CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment. Blood (ASH Annual Meeting Abstracts) 114(22):151 (#358), 11/2009.
68. Thomas D, Kantarjian H, Faderl S, Wierda W, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau S, Andreeff M, Garris R, Keating M, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood (ASH Meeting Abstracts) 114(22):344-345 (#836), 11/2009.
69. Badoux X, Keating M, O'Brien S, Kadia T, Ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda W. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1332-1333 (#3431), 11/2009.
70. Badoux X, Ramos C, Harris D, Li P, Liu Z, Burger JA, O'Brien S, Ferrajoli A, Keating M, Estrov Z. Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3. Blood (ASH Annual Meeting Abstracts) 114(22):511 (#1242), 11/2009.
71. Sivina M, Hartmann E, Keating M, Wierda W, Rosenwald A, Burger JA. Marrow Stromal Cells Induce TCL1 Expression in Chronic Lymphocytic Leukemia B Cells. Blood (ASH Annual Meeting Abstracts) 114(22):927 (#2347), 11/2009.
72. Badoux X, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo L, Wierda W. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. Blood (ASH Annual Meeting Abstracts) 114(22):513-514 (#1248), 11/2009.
73. Ravandi F, Kantarjian H, Thomas D, Faderl S, Jones D, Koller C, Dara S, Garris R, Kebriaei P, Champlin R Borthakur G, Wierda W, Burger JA, Cortes J, O'Brien S. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 114(22):345 (#837), 11/2009.
74. Garcia-Manero G, Tambaro F, Bekele F, Jabbour E, Ravandi F, Yang H, Borthakur G, Kadia T, Cortes J, Faderl S, Konopleva M, Pierce S, Burger JA, Estrov Z, O'Brien S, Thomas D, Newsome W, Kantarjian H. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 114(22):436 (#1055), 11/2009.
75. Batty N, Badoux X, Keating M, Lerner M, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda W. Pretreatment Factors Associated with Second Malignancies Occurring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 114(22):1339-1340 (#3448), 11/2009.
76. Kurtova A, Sivina M, Quiroga M, Wierda W, Keating MJ, Burger JA. The Immunophenotype Signature CD49d+CD38+ Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells. Blood (ASH Annual Meeting Abstracts) 114(22):150-151 (#356), 11/2009.
77. Schmitt-Graeff A, Bertz H, Metzger M, Strahm B, Stein H, Burger JA. Analysis of Clinico-Pathologic Features and Stromal Cell-Derived Factor (SDF)-1/CXCR4 in Myeloid Sarcoma. Blood (ASH Annual Meeting Abstracts) 112 (#3975), 11/2008.
78. Manshouri T, Estrov Z, Burger JA, Livun A, Zhang Y, Ma S, Gaikwad A, Harris D, Kantarjian H, Verstovsek S. Bone Marrow Stromal Cells Reverse Proapoptotic Effects of JAK2 Inhibitor Atiprimod in Cells Carrying the JAK2V617F mutation. Blood (ASH Annual Meeting Abstracts) 112 (#3738), 11/2008.
79. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Koller C, Estrov Z, Burger JA, Lerner S, Kantarjian H, Keating, M. CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. Blood (ASH Annual Meeting Abstracts) 112 (#2095), 11/2008.
80. Borthakur G, Estrov Z, Garcia-Manero G, Williams B, Wathen J, Konopleva M, Burger JA, Ferrajoli A, George S, Kantarjian H. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood (ASH Annual Meeting Abstracts) 112 (#2985), 11/2008.
81. Faderl S, Thomas D, Koller C, Ravandi F, Burger JA, O’Brien S, Dara S, Kantarjian H. Hyper-CVAD Plus Nelarabine: A Pilot Study for Patients with Newly Diagnosed T Cell Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112 (#3960), 11/2008.
82. Quiroga M, Kurtova A, Wierda W, Keating M, Burger JA. Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro-Survival Responses in CLL Cells. Blood (ASH Annual Meeting Abstracts) 112 (#2064), 11/2008.
83. Henderson J, O’Brien S, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Tam C, Burger JA, Abruzzo L, Schlette E, Lerner S, Keating M, Wierda W. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. Blood (ASH Annual Meeting Abstracts) 112 (#2078), 11/2008.
84. Wierda W, O’Brien S, Wang X, Faderl S, Ferrajoli A, Garcia-Manero G, Cortes J, Tam C, Burger JA, Abruzzo L, Schlette E, Lerner S, Keating M. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. Blood (ASH Annual Meeting Abstracts) 112 (#2094), 11/2008.
85. Kurtova A, Tamayo A, Ford, Jr. R, Burger JA. Migratory Activity and Stromal Cell Adhesion of Mantle Cell Lymphoma Cells Can Be Diminished by Blocking of VLA-4 and CXCR4 Receptors. Blood (ASH Annual Meeting Abstracts) 112 (#2825), 11/2008.
86. Thomas D, Kantarjian H, Faderl S, Wierda W, Ferrajoli A, Burger JA, Cortes J, Koller C, Borthakur G, Estrov Z, Konopleva M, Ravandi F, Garcia- Manero G, O’Brien S. Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood (ASH Annual Meeting Abstracts) 112 (#1931), 11/2008.
87. Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Dara S, Garris R, Kebriaei P, Borthakur G, Wierda W, Burger JA, Cortes J, O’Brien S. Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood (ASH Annual Meeting Abstracts) 112 (#2921), 11/2008.
88. Kurtova A, Quiroga M, Wierda W, Keating M, Burger JA. Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to Assess Cell Adhesion-Mediated Drug Resistance. Blood (ASH Annual Meeting Abstracts) 112 (#3149), 11/2008.
89. Cortes J, O'Brien S, Ferrajoli A, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). 2008 ASCO Annual Meeting (#7016), 5/2008.
90. Mattiuzzi G, Cortes J, Cassat J, Blamble D, Bekele B, Beran M, Borthakur G, Ravandi F, Burger JA, Kantarjian H. An Interim Analysis of Phase II, Open Randomized Comparative Trial: Alternate or Multiple-Day Dosing of Palonosetron (PALO) Is Effective and Safe in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients (pts) with Leukemia Receiving High Dose Ara-C (HDAC). 2007 ASH Annual Meeting & Exposition (#2840), 11/2007.
91. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger JA, Verstovsek S, Garcia-Manero G, Cortes J. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. 2007 ASH Annual Meeting & Exposition (#1939), 11/2007.
92. Quintás-Cardama A, Kantarjian H, Ravandi F, Burger JA, Borthakur G, Cortes J. Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy. 2007 ASH Annual Meeting & Exposition (#2958), 11/2007.
93. Quiroga M, Henneberg M, Niedermeier M, Burger JA. CD62L (L-Selectin), CXCR4, CD49d, and CD38 Contribute to Migration of Chronic Lymphocytic B Cells Beneath Marrow Stromal Cells. 2007 ASH Annual Meeting & Exposition (#1119), 11/2007. PMID: 19318683.
94. Jabbour E, Kantarjian H,Jones D, O’Brien S,Garcia-Manero G, Burger JA, Cortes J. Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs). 2007 ASH Annual Meeting & Exposition (#1949), 11/2007.
95. Wierda W, O’Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger JA, Schlette E, Abruzzo L, Lerner S, Keating M. Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. 2007 ASH Annual Meeting & Exposition (#2065), 11/2007.
96. Cortes J,O’Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger JA, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). 2007 ASH Annual Meeting & Exposition (#2481), 11/2007.
97. Burger JA, M Niedermeier , Bürkle A, Hartmann E, Wierda W, Keating M, Rosenwald A. High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation. 2007 ASH Annual Meeting & Exposition (#342), 11/2007.
98. Jain N, Kantarjian H, Fava C, Thomas D, Burger JA, Borthakur G, Pate O, Cortes J. Imatinib Dose Can Be Safely Reduced after Complete Cytogenetic Response (CCyR) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP) Treated with High-Dose Imatinib. 2007 ASH Annual Meeting & Exposition (#1043), 11/2007.
99. Niedermeier M, Rawluk J, Knight Z, Shokat K, Wierda W, Keating M, Burger JA. Importance of PI3 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B Cells and the Stromal Microenvironment: Therapeutic Implications. 2007 ASH Annual Meeting & Exposition (#1125), 11/2007.
100. Ravandi F, Faderl S, Thomas D, Burger JA, Koller C, Garcia-Manero G, Morris G, Torma R, Kantarjian H, Issa J. Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia. 2007 ASH Annual Meeting & Exposition (#897), 11/2007.
101. Faderl S, Thomas D, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger JA, Cortes J, O’Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian H. Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). 2007 ASH Annual Meeting & Exposition (#4335), 11/2007.
102. Tam C, Thomas D, Ravandi F, Richardson C, Borthakur G, Burger JA, Estey E, Kantarjian H, Verstovsek S. Phase II Evaluation of Sunitinib Malate, a Multi-Targeted Inhibitor of Receptor Tyrosine Kinases, in Patients with Myelofibrosis. 2007 ASH Annual Meeting & Exposition (#3552), 11/2007.
103. Alvarado Y, Kantarjian H, Faderl S, Burger JA,Borthakur G, O’Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). 2007 ASH Annual Meeting & Exposition (#1932), 11/2007.
104. Delmonte, Jr, J, Kantarjian H, Estey E, Ravandi F, Borthakur G, Burger JA, Pierce S, Cortes J. Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia. 2007 ASH Annual Meeting & Exposition (#3505), 11/2007.
105. Ravandi F, Verstovsek S, Estrov Z, Burger JA, George S, Bivens, C, Cortes-Franco J, Garrett W, Newton R, Kantarjian, H. Significant Activity of the JAK2 Inhibitor, INCB018424 in Patients with Secondary, Post-Myeloproliferative Disorder (MPD) Acute Myeloid Leukemia (sAML): Results of An Exploratory Phase II Study. Blood (ASH Meeting Abstracts) (#631), 12/2006.
106. Burger JA, Borthakur G, Pierce S, Kantarjian H, Estey E. Reproducibility of diagnosis in patients with myelodysplastic syndrome. 2006 ASCO Annual Meeting Vol 24, No. 18S (#16506), 6/2006.
107. Hartmann TN, Krome M, Burger JA. B-cell receptor signaling enhances migration of B-cell chronic lymphocytic leukemia cells in response to the chemokine stromal cell-derived factor-1 (SDF-1/CXCL12). Blood 106(11):347a Part 1, 2005.
108. Bürkle A, Burger JA. Overexpression of the CXCR5 Chemokine Receptor, and its ligand, B cell-activating chemokine-1 (BCA-1/CXCL13) in B cell chronic lymphocytic leukemia. Blood 106(11):824a Part 1, 2005.
109. Hartman T, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 and Integrin Signaling Lead to Higher Resistance to Chemotherapy Induced Apoptosis in Small Cell Lung Cancer (SCLC). Onkologie 27(Suppl.3):35, 2004.
110. Bürkle A, Schmitt-Gräff A, Krome M, Behringer D, Burger JA. Expression and function of the CXCR5 chemokine receptor on B lymphocytes from patients with B cell chronic lymphocytic leukemia and other B cell neoplasias. Supplement to The Hematology Journal, 9th Annual Congress of EHA, Geneva, 2004.
111. Berg T, Filegauf M, Pitako J, Burger JA, Abdelkarim M, Guo Y, Staege MS, Burdach S, Lübbert M. Induction of G1 Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: p53-Independent Upregulation of p21/WAF/CIPI1. Blood 104(11):2576a, 2004.
112. Bert T, Filegauf M, Pitako J, Burger JA, Abdelkarim M, Guo Y, Staege MS, Burdach S, Lubbert M. Induction of GI Arrest and Apoptosis in a Conditional Expression Model of AML1/ETO: p53-Independent Upregulation of p21/WAF/CIPI1. Blood 104(11):2576a, 2004.
113. Burger M, Hartmann T, Burger JA, Ingrid U. Schraufstatter. KSHV-GPCR and CXCR2 Transforming Capacity and Angiogenic Responses Are Mediated through a JAK2-STAT3 Dependent Pathway. Blood 104(11), 2004.
114. Burger M, Hartmann T, Burger JA, Schraufstatter I. KSHV-GPRC and CXCR2 Transforming Capacity and Angiogenic Responses are Mediated Through a JAK2-STAT3 Dependent Pathway. Onkologie 27(Suppl.3):164, 2004.
115. Spoo AC, Wierda WG, Burger JA. The CXCR4 Score: A New Prognostic Marker in Acute Myelogenous Leukemia. Blood 104(11):1072a, 2004.
116. Burger M, Hartmann T, Fujii N, Kipps TJ, Burger JA. CXCR4 chemokine receptor antagonists inhibit activation, migration, and survival of chronic lymphocytic leukemia B cells in response to stromal cell-derived factor-1 (SDF-1/CXCL12). Blood 102(11):1585a, 2003.
117. Zeiser R, Burger JA, Bley T, Windfuhr-Blum M, Schulte-Mönting J, Behringer D. Immunocytology of the cerebral spinal fluid as compared to magnetic resonance imaging in the diagnosis of leptomeningeal metastasis-a retrospective analysis. Onkologie 26(Suppl 5):224, 2003.
118. Rawluk J, Burger M, Burger JA. Signal transduction pathways of the CXCR4 chemokine receptor for migration and apoptosis of chronic lymphocytic leukemia B cells. Blood 102(11):1576a, 2003.
119. Rawluk J, Burger M, Burger JA. Signal transduction pathways of the Cxcr4 chemokine receptor for migration and apoptosis of chronic lymphocytic leukemia B-cells. Onkologie 26(Suppl 5):167, 2003.
120. Burger M, Schmitt-Gräff A, Glodek A, Silberstein LE, Tsukada N, Kipps TJ, Burger JA. CXCR4 chemokine receptors target small cell lung cancer metastasis to the bone marrow. Onkologie 25(Suppl 4):139, 2002.
121. Huber TB, Reinhardt HC, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H. Expression of functional CCR-and CXCR chemokine receptors in podocytes. J Am Soc Nephrol 13(Suppl S):349A, 2002.
122. Burger JA, Bürkle A, Behringer D. The chemokine B cell-activating chemokine-1 (BCA-1/CXCL13) is a powerful chemoattractant for chronic lymphocytic leukemia B cells. Onkologie 25(Suppl 4):173, 2002.
123. Burger JA, Burkle A, Behringer D. B cell chronic lymphocytic leukemia cells express functional CXCR5 chemokine receptors for the chemokine B cell-activating chemokine-1 (BCA-1/CXCL13). Blood 98(11):639a, 2001.
124. Burger JA, Tsukada N, Kipps TJ, Burger M. CXCR4 chemokine receptors target small cell lung cancer metastasis to the bone marrow. Blood 98(11):1239a, 2001.

Book Chapters

1. Burger JA. The CLL cell microenvironment. In: Adv Exp Med Biol. 792, 25-45, 2013. ISBN: 24014291.
2. Burger JA. Chronic Lymphocytic Leukemia (CLL): From Biology to Targeted Therapy. In: Treatment Strategies, Hematology. 2, 1. Cambridge Research Center,, 47-52, http://viewer.zmags.com/publication/48a268e2#/48a268e2/46, e-Book 2012.
3. Burger JA. Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience. In: Novel Developments in Stem Cell Mobilization. 1, 1. Ed(s) Stefan Fruehauf, w. Jens Zeller, Gary Calandra. Springer: New york, 369-386, 2012.
4. Burger JA and Sipkins DA. The bone marrow microenvironment and its impact in acute and chronic B cell malignancies. In: Bone Marrow Lymphoid Infiltrates -Diagnosis and Clinical Impact. Ed(s) Demi Anagnostou and Estella Matutes. Springer-Verlag: London, 2012.
5. Burger JA. Mechanisms of leukemia cell trafficking, homing, and tissue retention in chronic lymphocytic leukemia. In: Hematology Education, Program for the 16th Congress of the European Hematology Association. 5, 1, 91-99, 2011.
6. Burger JA. Chronic Lymphocytic Leukemia (CLL). In: Hematology und Internistische Onkologie, 3. Ed(s) DP Berger, R Engelhardt, R Mertelsmann. Das Rote Buch: Germany, 2006.

Letters to the Editor

1. Ponader S, Burger JA. Modeling the marrow stem cell niche in vitro: is proximity the key to reproduction? Haematologica 95(9):e5, 9/2010. PMCID: PMC2930977.

Grant & Contract Support

Title: 2013-0703: Randomized study of ibrutinib versus ibrutinib plus rituximab (i versus iR) in patients with relapsed chronic lymphocytic leukemia (CLL)
Funding Source: Pharmacyclics
Role: Principal Investigator
Duration: 11/27/2013 - 11/26/2018
 
Title: 2011-0513: Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, and Waldenstrom's Macroglobulinemia
Funding Source: Avila
Role: Principal Investigator
Duration: 6/11/2013 - 8/31/2016
 
Title: Understanding and overcoming mutant p53 mediated resistance in CLL
Funding Source: CLL Global Research Foundation
Role: Co-Investigator
Principal Investigator: Alfonso Quintas-Cardama, MD
Duration: 5/2/2013 - 5/1/2014
 
Title: 2012-1007 "A Randomized, Multicenter, Open-label, Phase 3 Study of the Btk Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive CLL or SLL"
Funding Source: Pharmacyclics
Role: Principal Investigator
Duration: 4/4/2013 - 4/3/2018
 
Title: Chronic Lymphocytic Leukemia Research Consortium Project 3 "Immune Therapy"
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Principal Investigator: Thomas Kipps, MD
Duration: 9/24/2012 - 8/31/2017
 
Title: Chronic Lymphocytic Leukemia Research Consortium: Project 2: Biochemistry of apoptosis in CLL
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Thomas Kipps, M.D.
Duration: 9/24/2012 - 8/31/2017
 
Title: 2012-0086: A Phase 2 Study to determine the effects of the Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using Heavy Water Labeling in subjects with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Funding Source: Pharmacyclics
Role: Principal Investigator
Duration: 2/15/2012 - 2/14/2017
 
Title: 2011-0785: A Phase 2 Study to determine the effects of the Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 on leukemia cell kinetics and trafficking, using Heavy Water Labeling in patients with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL
Funding Source: Pharmacyclics
Role: Principal Investigator
Duration: 1/30/2012 - 1/29/2017
 
Title: Targeting Microenvironment-Related Resistance in adult acute lymphoblastic leukemia (ALL) chemokine receptor: a new approach to overcome stromal cell-mediated drug resistance in Acute Lymphoblastic Leukemia (ALL)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 7/1/2011 - 12/30/2014
 
Title: 2010-0388: A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CAL101-08)
Funding Source: Gilead
Role: Principal Investigator
Duration: 12/13/2010 - 12/31/2014
 
Title: 2009-0536: Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 years) Adult Patients with Acute Myelogenous Leukemia (AML) with two or more unfavorable prognostic factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit
Funding Source: Genzyme
Role: Principal Investigator
Duration: 6/28/2010 - 6/30/2016
 
Title: Analysis of post treatment samples of PCI 32765
Funding Source: Pharmacyclics
Role: Principal Investigator
Duration: 6/3/2010 - 6/30/2015
 
Title: Dissecting the molecular pathways for cross-talk between Chronic Lymphocytic Leukemia cells and their microenvironment. 2. Effects of co-culture of CLL B cells with different stromal cells on sensitivity to anti-CLL drugs: towards a standardized assays to analyze cell adhesion-mediated drug-resistance
Funding Source: CLL Global Research Foundation
Role: Principal Investigator
Duration: 3/7/2008 - 8/31/2013
 
Title: Career Development Award: Improvement of current therapies with forodesine and fludarabine in chronic lymphocytic leukemia (CLL) by targeting the leukemia microenvironment
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2007 - 6/30/2011
 
Title: ASH Basic Research Scholar Award : The CXCR4 Chemokine Receptor: a New Prognostic Marker and Therapeutic Target in Acute Myelogenous Leukemia
Funding Source: American Society of Hematology (ASH)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: "Anatomy of the microenvironment in Chronic Lymphocytic Leukemia: focus on the chemokine CXCL13". New Investigator Grant.
Funding Source: Leukemia Research Foundation, Chicago, IL.
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: Kimmel Scholar Award
Funding Source: Sidney Kimmel Foundation for Cancer Research
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: Young Investigator Award: Targeting CXCR4 chemokine receptors and VLA-4 integrins in B cell lymphoid leukemias
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2007
 
Title: Microenvironmental regulation of survival and growth of B lymphocytes from patients with chronic lymphocytic leukemia (CLL)
Funding Source: CLL Global Research Foundation, Houston, Texas
Role: Principal Investigator
Duration: 12/29/2005 - 11/30/2008
 
Title: Expression and Function of the CXCR5 Chemokine Receptor, and its Ligand, CXCL13, in Chronic Lymphocytic Leukemia (CLL)
Funding Source: Lauri Strauss
Role: Principal Investigator
Duration: 1/1/2005 - 12/31/2005
 
Title: CXCR4 chemokine receptor antagonists for the treatment of chronic lymphocytic leukemia (CLL).
Funding Source: Jose Carreras Leukemia Society, Munich, Germany
Role: Principal Investigator
Duration: 9/1/2002 - 12/31/2006
 
Title: CXCR4 chemokine receptor signal transduction pathways in chronic lymphocytic leukemia (CLL).
Funding Source: Deutsche Krebshilfe, Bonn, Germany
Role: Principal Investigator-MDACC
Duration: 9/1/2001 - 3/30/2005

Last updated: 9/16/2014